Hot Investor Mandate: USA Life Sciences VC Firm Invests Up to $8M in Therapeutics Companies Addressing Unmet Medical Need with Unique MOA

25 Mar

A life sciences venture capital firm based in USA is focused on early and growth-stage biotech and pharma companies. The group has $300M assets under management and recently closed its third fund. Initial investments typically are in the $3M-$8M range and are usually in the form of equity, but may use convertible notes in select situations. The firm look to take meaningful stake in portfolio companies and play an active role in their development. The firm is open to companies based in the U.S., with a specific interest in companies located outside of the major biotech hubs of Boston and San Francisco.

The firm is most interested in the biotech/therapeutics space. The firm does not invest in diagnostic or healthcare IT companies. The firm is mostly opportunistic in terms of technology type and indication area; however, the group prioritizes companies with products addressing unmet medical needs and unique mechanisms of action. Bios typically invests in companies ranging from late preclinical to Ph. II clinical trials.

The firm has no strict company or management team requirements, but does look to be a very active investor and always requires a board seat along with an investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: